Literature DB >> 2384671

The role of humoral immunity in Cryptosporidium spp. infection. Studies with B cell-depleted mice.

R Taghi-Kilani1, L Sekla, K T Hayglass.   

Abstract

Cryptosporidiosis has become an important infection in man, particularly among very young or immunocompromised individuals. Here, the protective role of antibody responses to Cryptosporidium was examined using a well established murine model of cryptosporidiosis. Although normal neonatal BALB/c mice exhibited good IgM and IgG serum antibody responses, no correlation could be drawn between the intensity of these responses and the severity or duration of cryptosporidiosis. Moreover, B cell-deficient (anti-mu-treated) neonatal BALB/c mice did not differ from untreated or normal rabbit Ig-treated, age-matched controls in the onset, peak, or duration of cryptosporidiosis. The apparent absence of a role for antibody in these self resolving infections was supported by the lack of susceptibility of anti-mu-treated adult BALB/c to attempted infection with doses of Cryptosporidium 10 times the dose required to infect 100% of normal (Ig producing) neonates. The results suggest that the role of specific in vivo antibody responses in the resolution of murine infection with this coccidian parasite is minor and that the likelihood of success for cryptosporidial vaccines aimed solely at enhancing in vivo antibody production may be limited.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2384671

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Effects of in vivo T-cell depletion on immunity to Eimeria falciformis.

Authors:  K T HayGlass
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

Review 2.  Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients.

Authors:  Paul R Hunter; Gordon Nichols
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

3.  Immune responses to Cryptosporidium muris and Cryptosporidium parvum in adult immunocompetent or immunocompromised (nude and SCID) mice.

Authors:  V McDonald; R Deer; S Uni; M Iseki; G J Bancroft
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

4.  Kinetics of Cryptosporidium parvum-specific cytokine responses in healing and nonhealing murine models of C. parvum infection.

Authors:  Inderpal Singh; Cynthia Theodos; Wenjun Li; Saul Tzipori
Journal:  Parasitol Res       Date:  2005-07-29       Impact factor: 2.289

5.  Profiles of healing and nonhealing Cryptosporidium parvum infection in C57BL/6 mice with functional B and T lymphocytes: the extent of gamma interferon modulation determines the outcome of infection.

Authors:  C M Theodos; K L Sullivan; J K Griffiths; S Tzipori
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

6.  Evidence of thymus-independent local and systemic antibody responses to Cryptosporidium parvum infection in nude mice.

Authors:  A A Adjei; J T Jones; M W Riggs; F J Enriquez
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

7.  Age-related resistance in ovine cryptosporidiosis: patterns of infection and humoral immune response.

Authors:  L M Ortegà-Mora; S E Wright
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

8.  Cryptosporidium muris in adult mice: adoptive transfer of immunity and protective roles of CD4 versus CD8 cells.

Authors:  V McDonald; H A Robinson; J P Kelly; G J Bancroft
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

9.  Cryptosporidium parvum infection in T-cell receptor (TCR)-alpha- and TCR-delta-deficient mice.

Authors:  W R Waters; J A Harp
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

10.  Serum immunoglobulin G, M and A response to Cryptosporidium parvum in Cryptosporidium-HIV co-infected patients.

Authors:  Kirti Kaushik; Sumeeta Khurana; Ajay Wanchu; Nancy Malla
Journal:  BMC Infect Dis       Date:  2009-11-18       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.